

March 10, 2021

Stayble appoints Professor Hans Jörg Meisel as a member of the scientific advisory board

Stayble Therapeutics today announced that the company's scientific advisory board gains new expertise through the appointment of Professor Hans Jörg Meisel, Berlin, Germany. Prof. Meisel adds further expertise in medical innovation and clinical trials in degenerative spinal diseases and a European perspective to the company's scientific advisory board.

Anders Lehmann, Chief Scientific Officer comments: "We are excited about the appointment of Prof. Meisel, a leading expert in advanced therapies for low back pain with a long-standing and extensive experience in spinal diseases. His appointment to Stayble's scientific advisory board provides us with more expertise in clinical development and ensures that we always have first-hand insights from both key markets, US and Europe."

Hans Jörg Meisel, MD, PhD, Prof., is Director of the Center of Neurosciences and the Chair of the Department of Neurosurgery at the BG-Clinic Bergmannstrost Halle, Berlin, Germany. Prof. Meisel was one of the founding members of AO Spine Europe and is currently one of the steering committee members of AO Spine Knowledge Forum Degenerative and leading the AOGO project, creating a guideline for using osteobiologics in patients with spinal degeneration.

Prof. Meisel is an inventor and designer of spinal implants, and developed the first biological disc repair transplantation system with autologous chondrocytes in 1995. He has since then expanded his clinical trial expertise by initiating the EU Project 'RESPINE' together with colleagues in 2016. Prof Meisel has also co-founded several organizations. For example, he is a founding member of the European Commission's European Technology Platform Nanomedicine, where he also served as chair of the Working Group of Nanotechnologies for Regenerative Medicine. Due to his extensive knowledge, Prof. Meisel was appointed to become a Visiting Professor at the Department of Orthopedic Surgery at the Vrije University of Amsterdam in 2007 and became Honorary Professor at the Department for Health Sciences and Biomedicine at the Donau-University Krems in Austria in 2013.

For more information

Andreas Gerward, CEO Stayble Therapeutics AB
andreas.gerward@stayble.se,
+46 730 808 397

About Stayble Therapeutics AB

Stayble is a clinical stage pharmaceutical company developing the injection treatment STA363 for disc-related low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and painkillers. The injection is given once and the effect is expected to remain throughout the entirety of the patient's life and to require minimal rehabilitation. The Company's focus is set upon the continued clinical development and is currently conducting a clinical phase 2b. Stayble's vision is to develop STA363 as a new standard treatment for patients suffering from chronic disc-related low back pain.

Mangold Fondkommission AB is the Company's Certified Adviser and can be reached at +46 (0)8 503 015 50 or e-mail ca@mangold.se. More information on www.staybletherapeutics.com.